NOT-DA-19-013: Notice of Correction to Application Types Allowed for RFA-DA-19-019, "HEAL Initiative: Americas Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44

Notice of Correction to Application Types Allowed for RFA-DA-19-019, "HEAL Initiative: America?s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional)"

Notice Number: NOT-DA-19-013

Key Dates
Release Date: December 19, 2018

Related Announcements
RFA-DA-19-019

Issued by
National Institute on Drug Abuse (NIDA)
National Center for Advancing Translational Sciences (NCATS)

Purpose

The purpose of this Notice is to change the Application Types Allowed for RFA-DA-19-019, "HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional)."

The following section has been modified:

Section II. Award Information

Currently reads:

Application Types Allowed

New (Phase I)

Renewal (Phase II* Direct Phase II not allowed)
New (Fast-Track)

Resubmissions
Revisions

Should correctly read(in italics):

Application Types Allowed

New (Phase I)

Renewal (Phase II and Direct Phase II allowed)
New (Fast-Track)

Resubmissions
Revisions

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Elena Koustova, PhD, MBA
National Institute on Drug Abuse (NIDA)
Telephone:301-496-8768
Email:NIDASBIR@mail.nih.gov